These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19762089)

  • 1. Sodium valproate: an old drug with new roles.
    Nalivaeva NN; Belyaev ND; Turner AJ
    Trends Pharmacol Sci; 2009 Oct; 30(10):509-14. PubMed ID: 19762089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
    Harrison IF; Crum WR; Vernon AC; Dexter DT
    Br J Pharmacol; 2015 Aug; 172(16):4200-15. PubMed ID: 26040297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: Role of HDAC inhibition.
    Patel MM; Patel BM
    Eur J Pharm Sci; 2018 Aug; 121():188-199. PubMed ID: 29852291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate.
    Demyanenko SV; Dzreyan VA; Uzdensky AB
    Brain Res Bull; 2020 Sep; 162():151-165. PubMed ID: 32592806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke.
    Faggi L; Pignataro G; Parrella E; Porrini V; Vinciguerra A; Cepparulo P; Cuomo O; Lanzillotta A; Mota M; Benarese M; Tonin P; Annunziato L; Spano P; Pizzi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
    Ziemka-Nalecz M; Jaworska J; Sypecka J; Zalewska T
    J Neuropathol Exp Neurol; 2018 Oct; 77(10):855-870. PubMed ID: 30165682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium valproate enhances doxorubicin-induced cognitive dysfunction in Wistar rats.
    Verma T; Mallik SB; Ramalingayya GV; Nayak PG; Kishore A; Pai KSR; Nandakumar K
    Biomed Pharmacother; 2017 Dec; 96():736-741. PubMed ID: 29049976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate and neuroprotection.
    Vajda FJ
    J Clin Neurosci; 2002 Sep; 9(5):508-14. PubMed ID: 12383405
    [No Abstract]   [Full Text] [Related]  

  • 9. Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery.
    Williams JA; Barreiro CJ; Nwakanma LU; Lange MS; Kratz LE; Blue ME; Berrong J; Patel ND; Gott VL; Troncoso JC; Johnston MV; Baumgartner WA
    Ann Thorac Surg; 2006 Jun; 81(6):2235-41; discussion 2241-2. PubMed ID: 16731160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.
    Leng Y; Chuang DM
    J Neurosci; 2006 Jul; 26(28):7502-12. PubMed ID: 16837598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tescalcin is a potential target of class I histone deacetylase inhibitors in neurons.
    Takamatsu G; Katagiri C; Tomoyuki T; Shimizu-Okabe C; Nakamura W; Nakamura-Higa M; Hayakawa T; Wakabayashi S; Kondo T; Takayama C; Matsushita M
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1327-1333. PubMed ID: 27939885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives of valproic acid in clinical practice.
    Činčárová L; Zdráhal Z; Fajkus J
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1535-47. PubMed ID: 24160174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone acetylation for neuroprotection.
    Contestabile A
    Curr Pharm Des; 2013; 19(28):5017-8. PubMed ID: 23448467
    [No Abstract]   [Full Text] [Related]  

  • 14. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
    Löscher W
    CNS Drugs; 2002; 16(10):669-94. PubMed ID: 12269861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.
    Perucca E
    CNS Drugs; 2002; 16(10):695-714. PubMed ID: 12269862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Valproic acid as a histone deacetylase inhibitor. New application for a well-known drug].
    Wagner JM; Bug G; Jung M
    Pharm Unserer Zeit; 2010 May; 39(3):197-203. PubMed ID: 20425769
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium Valproate, a Histone Deacetylase Inhibitor, Provokes Reactive Oxygen Species-Mediated Cytotoxicity in Human Hepatocellular Carcinoma Cells.
    Rithanya P; Ezhilarasan D
    J Gastrointest Cancer; 2021 Mar; 52(1):138-144. PubMed ID: 32006341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.
    Monti B; Polazzi E; Contestabile A
    Curr Mol Pharmacol; 2009 Jan; 2(1):95-109. PubMed ID: 20021450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors and neurodegeneration: at the edge between protection and damage.
    Dietz KC; Casaccia P
    Pharmacol Res; 2010 Jul; 62(1):11-7. PubMed ID: 20123018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
    Kim HJ; Rowe M; Ren M; Hong JS; Chen PS; Chuang DM
    J Pharmacol Exp Ther; 2007 Jun; 321(3):892-901. PubMed ID: 17371805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.